Aira.IO grabs over $2.5 mln

By Iris Dorbian — 1 week ago

Aira.IO, a visual interpreter for the blind, has raised over $2.5 million in Series A financing. Lux Capital and ARCH Venture Partners led the round with participation from other investors that included Felicis Ventures and Larry Bock.

Continue

Accelerator Corp launches Lodo Therapeutics, which raises $17 mln

By Iris Dorbian — 1 month ago

Accelerator Corp has formed Lodo Therapeutics Corp, which has secured $17 million in Series A funding. The investors included AbbVie, Alexandria Venture Investments, ARCH Venture Partners, Eli Lilly and Company, Harris & Harris Group, Inc., Innovate NY Fund, Johnson & Johnson Innovation – JJDC, Inc., The Partnership Fund for New York City and Pfizer Venture Investments. Based in New York City, Lodo Therapeutics Corp is a developer of  therapeutics derived from Accelerator’s metagenomics-based small molecule discovery platform.

Continue

Petra Pharma racks up $48 mln Series A

By Iris Dorbian — 1 month ago

Petra Pharma Corp, a startup focused on treating cancer and metabolic diseases that was launched by Accelerator Corp, has raised $48 million in Series A funding. The investors included AbbVie, Alexandria Venture Investments, ARCH Venture Partners, Eli Lilly and Company, Harris & Harris Group, Inc., Innovate NY Fund, Johnson & Johnson Innovation – JJDC, Inc, The Partnership Fund for New York City, Pfizer Venture Investments, Watson Fund and WuXi PharmaTech.

Continue

VC-backed Kura Oncology goes public

By Iris Dorbian — 3 months ago

La Jolla, California-based Kura Oncology Inc, a biopharmaceutical company focused on treating solid tumors and blood cancers, has raised $50 million for its IPO after pricing its 6.25 million shares at $8 per share. The stock began trading Thursday on the NASDAQ under the ticker symbol “KURA.” Citigroup and Leerink Partners are serving as lead […]

Continue

Aira snags $790K

By Iris Dorbian — 4 months ago

Aira.IO, a visual interpreter for the blind, has raised $790,000 in seed financing. Lux Capital and ARCH Venture Partners led the round.

Continue

Accelerator Corp raises $62.8 mln for fourth fund

By Iris Dorbian — 5 months ago

Accelerator Corp has closed its oversubscribed fourth fund at $62.8 million. The limited partners of Accelerator IV include AbbVie, WuXi PharmaTech, Watson Fund, Alexandria Venture Investments, ARCH Venture Partners, Eli Lilly and Company, Johnson & Johnson Innovation – JJDC Inc, Pfizer Venture Investments and WRF Capital. The pool will focus on early-stage life science investments. In addition to the fund, Accelerator has named Dr. James P. Sullivan, Dr. Tadataka Yamada and Peter Cheney to its board of directors.

Continue

AgBiome picks up $34.5 mln Series B

By Iris Dorbian — 6 months ago

Research Triangle Park, North Carolina-based AgBiome LLC, an agricultural products developer, has raised $34.5 million in Series B funding. The investors included Bill & Melinda Gates Foundation, the University of Texas Investment Management Company, Pontifax Global Food and Agriculture Technology Fund, Polaris Partners, ARCH Venture Partners, Harris & Harris Group, Innotech Advisers, Monsanto Growth Ventures and Syngenta Ventures.

Continue

Voxel8 snaps up $12 mln Series A

By Iris Dorbian — 7 months ago

Somerville, Massachusetts-based Voxel8, a multi-material 3D electronics printer maker, has raised $12 million in Series A funding. Braemar Energy Ventures and ARCH Venture Partners led the round with participation from Autodesk and In-Q-Tel.

Continue

Arivale raises $36 mln

By Luisa Beltran — 7 months ago

Arivale said Tuesday it raised $36 million in Series B funding led by ARCH Venture Partners and Polaris Partners. Maveron also participated. Seattle-based Arivale is a scientific wellness company.

Continue

Denali launches with $217 mln

By Iris Dorbian — 9 months ago

Denali Therapeutics Inc, a developer of treatments for neurodegenerative diseases, has launched with a $217 million investment commitment. The investors include Fidelity Biosciences, ARCH Venture Partners, Flagship Ventures and the Alaska Permanent Fund.

Continue

Movidius racks up $40 mln

By Iris Dorbian — 10 months ago

San Mateo, California-based vision processor company Movidius has secured $40 million in funding. Summit Bridge Capital, a joint venture between Atlantic Bridge Capital and WestSummit Capital, led the round with other investors that included ARCH Venture Partners, Sunny Optical Technology Group, AIB Seed Capital Fund, Capital-E, DFJ Esprit and Robert Bosch Venture Capital. In addition to the funding, David Lam of WestSummit Capital has been appointed to Movidius’ board of directors.

Continue

Semma Therapeutics nets $44 mln

By Iris Dorbian — 11 months ago

Cambridge, Massachusetts-based Semma Therapeutics, a developer of cell therapy for Type 1 diabetes, has secured $44 million in Series A funding. MPM Capital led the round with participation from Fidelity Biosciences, ARCH Venture Partners and Medtronic. Also, the company has named Stephen Oesterle, senior vice president for medicine and technology at Medtronic, as a board observer.

Continue

Kura Oncology snags $60 mln

By Iris Dorbian — 11 months ago

La Jolla, California-based Kura Oncology Inc, a biopharmaceutical company focused on treating solid tumors and blood cancers, has raised $60 million in a private placement. EcoR1 Capital was the lead investor. Other investors included Fidelity Management & Research Company, ARCH Venture Partners, Tavistock Life Science’s Boxer Capital, Partner Fund Management and Nextech Invest. Leerink Partners LLC was lead placement agent while National Securities Corp and Livingston Securities LLC were co-placement agents for the private placement.

Continue

Chiasma snags $70 mln Series E

By Iris Dorbian — 12 months ago

Chiasma Inc has received $70 million in Series E financing. The investors included Rock Springs Capital, Sofinnova Ventures, MPM Capital, F2 Capital, 7 Med Health Ventures, Abingworth and ARCH Venture Partners. Headquartered in Newton, Massachusetts and Jerusalem, Chiasma is a biopharmaceutical firm focused on treating acromegaly.

Continue

VC-backed Juno Therapeutics rolls out IPO

By Iris Dorbian — 1 year ago

Juno Therapeutics has debuted its IPO after pricing its over 11 million shares at $24 per share. The stock began trading Friday on the NASDAQ under the ticker symbol “JUNO.” Morgan Stanley, J.P. Morgan Securities and Goldman Sachs are the lead underwriters. Based in Seattle, Juno is a biotech company focused on developing immunotherapies for cancer. Its backers include Bezos Expeditions, Venrock, ARCH Venture Partners and the Alaska Permanent Fund.

Continue